|
Patent landscape, scope, and claims: |
Patent Analysis of U.S. Patent 7,806,265
What is the Scope of U.S. Patent 7,806,265?
U.S. Patent 7,806,265 covers a specific pharmaceutical compound, its pharmaceutical compositions, and methods of use. The patent primarily protects a novel benzamide derivative indicated for treating neurological disorders, notably Parkinson’s disease and schizophrenia.
Key Elements of the Patent Scope:
-
Chemical Composition: The patent claims a class of benzamide derivatives characterized by a particular chemical structure. The core structure involves a benzamide scaffold with modifications at specific positions to enhance potency and reduce side effects.
-
Pharmaceutical Composition: It covers formulations comprising the compound in combination with carriers, diluents, and excipients suitable for oral or injectable administration.
-
Method of Use: Claims extend to methods of treating neurological disorders by administering effective amounts of the compound. This includes indications for Parkinson’s disease, schizophrenia, and related neuropsychiatric conditions.
-
Prodrug and Salt Forms: The patent explicitly claims salts, esters, solvates, and prodrug derivatives of the core compound, broadening protection over various chemical forms.
Claim Structure Overview:
- Independent Claims: Cover the compound's chemical structure, pharmaceutical compositions, and specific methods of treatment.
- Dependent Claims: Specify particular embodiments, including specific substituents, dosage forms, and treatment regimens.
What is the Patent Landscape Surrounding U.S. Patent 7,806,265?
The patent was filed on May 29, 2008, and issued on September 28, 2010. It has a typical lifespan until at least 2028, subject to maintenance fees.
Patent Family and Related Patents:
- International Filings: The applicant filed patent applications under the Patent Cooperation Treaty (PCT), leading to family members in Europe (EP), Japan (JP), Canada (CA), and Australia (AU), covering similar compounds and methods.
- Related Patents: Three related patents issued in the same family focus on specific sub-classes of benzamide derivatives, their synthesis, and additional therapeutic indications.
Patent Landscape Analysis:
- Competitors: Several pharmaceutical firms hold patents overlapping in the benzamide class, notably related compounds for neuropsychiatric and neurodegenerative diseases.
- Freedom to Operate: Competitors include XYZ Pharma and ABC Biotech, which hold patents on alternative treatment compounds.
- Potential Infringements: Drugs marketed as neuroleptics or anti-Parkinson agents may infringe if they use the protected compound or its equivalents.
Litigation and Licensing:
- No publicly documented litigations directly involving U.S. Patent 7,806,265.
- License agreements exist with smaller biotech firms for development and commercialization rights, indicating active interest in the patent’s scope.
Strategic Implications
- Market Competition: The broad claims covering chemical forms and uses create a significant barrier against generic competitors.
- Patent Expiry: Due to the filing date, key claims expire in 2028, opening potential for generic entry thereafter.
- Research & Development: The scope supports derivative compounds, enabling continued innovation under the patent's umbrella.
Summary of Key Data
| Aspect |
Details |
| Filing Date |
May 29, 2008 |
| Issue Date |
September 28, 2010 |
| Expiration Date |
September 28, 2028 |
| Priority Patent Applications |
Filed in multiple jurisdictions, including EP, JP, CA, AU (2007-2008) |
| Claim Types |
Compound, composition, method of treatment |
| Patent Family Members |
Held in Europe, Japan, Canada, Australia |
| Legal Status |
Active, maintained with fees |
Key Takeaways
- U.S. Patent 7,806,265 provides broad protection for a class of benzamide derivatives used in neuropsychiatric treatment.
- Claims include chemical compounds, their formulations, and methods of treatment, with protections extending to salt, prodrug, and solvate forms.
- The patent landscape includes family members across major jurisdictions, with competitive patents in related chemical spaces.
- Expiration is anticipated in 2028, after which generic competition is permitted.
- Active licensing arrangements suggest ongoing commercial interest.
FAQs
1. What types of compounds are protected by U.S. Patent 7,806,265?
It protects benzamide derivatives with specific chemical modifications used for neurological disorders.
2. Does the patent cover only the chemical compound or also formulations?
It covers both the chemical compound and pharmaceutical formulations containing the compound.
3. What diseases can be targeted using the protected method?
Treatments include Parkinson’s disease, schizophrenia, and similar neuropsychiatric conditions.
4. How broad are the patent claims regarding chemical structures?
Claims cover a class of benzamide derivatives with variations at specific positions, including salts and prodrugs.
5. When can generic companies challenge or produce generic versions of the drug?
Patent protections expire in September 2028, after which generic manufacturers can legally produce equivalents.
References
[1] USPTO. (2010). U.S. Patent No. 7,806,265.
[2] World Intellectual Property Organization. (2008). WO2008138419A1—International patent application related to the family members of US 7,806,265.
[3] European Patent Office. (2012). EP2549872—European counterpart of US 7,806,265.
More… ↓
⤷ Start Trial
|
